Chimeric antigen receptor therapy has revolutionized hematology but is there ways we could further improve the immune cells that delivery the therapy?
In this episode we talk to Professor Satu Mustjoki and Dr Olli Dufva and their recent paper ‘Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity’ (Link: https://ashpublications.org/blood/article/135/9/597/429647/Integrated-drug-profiling-and-CRISPR-screening) in Blood. We discuss how T cell responses are modified by drugs that could be used in combination with cellular therapies and how they can both enhance and inhibit CAR T cells functioning. We also get into the molecular mechanisms by which is thought to happen in a number of hematological cancer cells.
You can follow Dr. Olli Dufva and Profesor Mustjoki on twitter at: https://twitter.com/ollidufva and https://twitter.com/hruh_research. Read more about Professor Satu Mustjoki and her group here: https://www2.helsinki.fi/en/researchgroups/hematology-research-unit-helsinki/people
Podden och tillhörande omslagsbild på den här sidan tillhör KITE Gilead. Innehållet i podden är skapat av KITE Gilead och inte av, eller tillsammans med, Poddtoppen.
